• A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.

  Spiciarich DR, Oh ST, Foley A, Hughes SB, Mauro MJ, Abdel-Wahab O, Press RD, Viner R, Thompson SL, Chen Q, Azadi P, Bertozzi CR, Maxson JE.
  Cancer Res. 2018 Dec 15;78(24):6762-6770. doi: 10.1158/0008-5472.CAN-18-1638.

• Organoid Modeling of the Tumor Immune Microenvironment.

  Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K, Schultz LM, Metzner TJ, Nadauld LD, Tseng YY, Alkhairy S, Oh C, Keskula P, Mendoza-Villanueva D, De La Vega FM, Kunz PL, Liao JC, Leppert JT, Sunwoo JB, Sabatti C, Boehm JS, Hahn WC, Zheng GXY, Davis MM, Kuo CJ.
  Cell. 2018 Dec 13;175(7):1972-1988.e16. doi: 10.1016/j.cell.2018.11.021.

• Two myeloid leukemia cases with rare FLT3 fusions.

  Zhang H, Paliga A, Hobbs E, Moore S, Olson S, Long N, Dao KT, Tyner JW.
  Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6):a003079. doi: 10.1101/mcs.a003079.

• Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.

  Calcinotto A, Brevi A, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, Kumar S, Garbitt VM, Sharik ME, Henderson KJ, Tonon G, Tomura M, Miwa Y, Esplugues E, Flavell RA, Huber S, Canducci F, Rajkumar VS, Bergsagel PL, Bellone M.
  Nat Commun. 2018 Dec 3;9(1):4832. doi: 10.1038/s41467-018-07305-8.

• T Helper Cell Cytokines Modulate Intestinal Stem Cell Renewal and Differentiation.

  Biton M, Haber AL, Rogel N, Burgin G, Beyaz S, Schnell A, Ashenberg O, Su CW, Smillie C, Shekhar K, Chen Z, Wu C, Ordovas-Montane J, Alvarez D, Herbst RH, Zhang M, Tirosh I, Dionne D, Nguyen LT, Xifaras ME, Shalek Ak, von Andrian UH, Graham DB, Rozenblatt-Rosen O, Shi HN, Kuchroo V, Yilmaz OH, Regev A, Xavier RJ.
  Cell. 2018 Nov 15;175(5):1307-1320.e22. doi: 10.1016/j.cell.2018.10.008.

• Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

  Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Are AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.
  Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038.

• Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

  Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.
  J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184.

• Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.

  Chosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JW, Agarwal A.
  Leukemia. 2018 Nov;32(11):2374-2387. doi: 10.1038/s41375-018-0112-2.

• Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.

  Nanjo S, Bivona TG.
  J Thorac Dis. 2018 Nov;10(Suppl 33):S4061-S4064. doi: 10.21037/jtd.2018.09.106.

• Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma.

  Bianchi-Smiraglia A, Bagati A, Fink EE, Affronti HC, Lipchick BC, Moparthy S, Long MD, Rosario SR, Lightman SM, Moparthy K, Wolff DW, Yun DH, Han Z, Polechetti A, Roll MV, Gitlin II, Leonova KI, Rowsam AM, Kandel ES, Gudkov AV, Bergsagel PL, Lee KP, Smiraglia DJ, Nikiforov MA.
  J Clin Invest. 2018 Oct 1;128(10):4682-4696. doi: 10.1172/JCI70712.

• Functional genomic landscape of acute myeloid leukaemia.

  Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KHT, Degnin M, Devine D, Dibb J, Edwards 5th DK, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney Sk, Druker BJ.
  Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z.

• Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast.

  Siravegna G, Corcoran RB.
  Cancer Discov. 2018 Oct;8(10):1213-1215. doi: 10.1158/2159-8290.CD-18-0952.

• TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.

  Blee AM, He Y, Yang Y, Ye Z, Yan Y, Pan Y, Ma T, Dugdale J, Kuehn E, Kohli M, Jimenez R, Chen Y, Xu W, Wang L, Huang H.
  Clin Cancer Res. 2018 Sep 15;24(18):4551-4565. doi: 10.1158/1078-0432.CCR-18-0653.

• Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.

  Singer JW, Fleischman, Al-Fayoumi S, Mascarenhas JO, Yu Q, Agarwal A.
  Oncotarget. 2018 Sep 7;9(70):33416-33439. doi: 10.18632/oncotarget.26058.

• Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.

  Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, Schultz N, Taylor B, Vickers A, Cuzick J, Sawyers CL.
  Elife. 2018 Sep 4;7:e37294. doi: 10.7554/eLife.37294.

• RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.

  Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG.
  Nat Cell Biol. 2018 Sep;20(9):1064-1073. doi: 10.1038/s41556-018-0169-1.

• Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

  Kurtz SE< Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW.
  Leukemia. 2018 Sep;32(9):2025-2028. doi: 10.1038/s41375-018-0225-7.

• Detailing the genomic landscape of myeloma.

  Bergsagel PL, Kuehl WM.
  Blood. 2018 Aug 9;132(6):554-555. doi: 10.1182/blood-2018-06-857508.

• Dietary regulation of the origins of cancer.

  Yilmaz ÖH.
  Sci Transl Med. 2018 Aug 8;10(453):eaat8285. doi: 10.1126/scitranslmed.aat8285.

• Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia.

  Watanabe-Smith K, Druker BJ, Tyner JW, Edwards 5th DK.
  Haematologica. 2018 Aug;103(8):e351-e355. doi: 10.3324/haematol.2018.190926.

• Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.

  Jenkins C, Luty SB, Maxson JE, Eide CA, Abel ML, Togiai C, Nemecek ER, Bottomly D, McWeeney SK, Wilmot B, Loriaux M, Chang BH, Tyner JW.
  Sci Signal. 2018 Jul 17;11(539):eaao5617. doi: 10.1126/scisignal.aao5617.

• Patient derived organoids to model rare prostate cancer phenotypes.

  Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanu DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H.
  Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z.

• Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.

  Chen Y, Chi P.
  J Hematol Oncol. 2018 Jun 7;11(1):78. doi: 10.1186/s13045-018-0622-4.

• Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

  Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, Manier S, Mishima Y, Murakami N, Bustoros M, Pistofidis RS, Reidy M, Shen YJ, Rahmat M, Lukyanchykov P, Karreci ES, Tsukamoto S, Shi J, Takagi S, Huynh D, Sacco A, Tai YT, Chesi M, Bergsagel PL, Roccaro AM, Azzi J, Ghobrial IM.
  J Clin Invest. 2018 Jun 1;128(6):2487-2499. doi: 10.1172/JCI88169. Epub 2018 May 14.

• TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.

  Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA.
  J Clin Invest. 2018 Jun 1;128(6):2500-2518. doi: 10.1172/JCI96148.

• Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.

  Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM.
  Oncotarget. 2018 May 15;9(37):24576-24589. doi: 10.18632/oncotarget.25191.

• A Convergence-Based Framework for Cancer Drug Resistance.

  Konieczkowski DJ, Johannessen CM, Garraway LA.
  Cancer Cell. 2018 May 14;33(5):801-815. doi: 10.1016/j.ccell.2018.03.025.

• Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.

  Zhang H, Coblentz C, Watanabe-Smith K, Means S, Means J, Maxson JE, Tyner JW.
  J Biol Chem. 2018 May 11;293(19):7387-7396. doi: 10.1074/jbc.RA118.002417.

• Fasting Activates Fatty Acid Oxidation to Enhance Intestinal Stem Cell Function during Homeostasis and Aging.

  Mihaylova MM, Cheng CW, Cao AQ, Tripathi S, Mana MD, Bauer-Rowe KE, Abu-Remaileh M, Clavain L, Erdemir A, Lewis CA, Freinkman E, Dickey AS, La Spada AR, Huang Y, Bell GW, Deshpande V, Carmeliet P, Katajisto P, Sabatini DM, Yilmaz OH.
  Cell Stem Cell. 2018 May 3;22(5):769-778.e4. doi: 10.1016/j.stem.2018.04.001.

• Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.

  Zaman A, Bivona TG.
  Ann Transl Med. 2018 May;6(9):160. doi: 10.21037/atm.2018.05.02.

• Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

  Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.
  Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038.

• The long tail of oncogenic drivers in prostate cancer.

  Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM.
  Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z.

• Automation of ReactomeFIViz via CyREST API.

  Loney F, Wu G.
  F1000Res. 2018 May 2;7:531. doi: 10.12688/f1000research.14776.2.

• EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes.

  Harding T, Swanson J, Van Ness B.
  Oncotarget. 2018 Apr 24;9(31):21930-21942. doi: 10.18632/oncotarget.25128.

• Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF^V600E Colorectal Cancer.

  Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski Jr JM, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB.
  Cancer Discov. 2018 Apr;8(4):417-427. doi: 10.1158/2159-8290.CD-17-1227.

• Challenges in validating candidate therapeutic targets in cancer.

  Settleman J, Sawyers CL, Hunter T.
  Elife. 2018 Feb 8;7:e32402. doi: 10.7554/eLife.32402.

• Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia.

  Lamble AJ, Dietz M, Laderas T, McWeeney S, Lind EF.
  J Immunol Methods. 2018 Feb;453:44-52. doi: 10.1016/j.jim.2017.11.010.

• Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

  Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KM, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S.
  Cancer Discov. 2018 Feb;8(2):164-173. doi: 10.1158/2159-8290.CD-17-1009.

• Antigen-mediated regulation in monoclonal gammopathies and myeloma.

  Nair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV.
  JCI Insight. 2018 Apr 19;3(8):e98259. doi: 10.1172/jci.insight.98259.

• Phospholipid Remodeling and Cholesterol Availability Regulate Intestinal Stemness and Tumorigenesis.

  Wang B, Rong X, Palladino END, Wang J, Fogelman AM, Martín MG, Alrefai WA, Ford DA, Tontonoz P.
  Cell Stem Cell. 2018 Feb 1;22(2):206-220.e4. doi: 10.1016/j.stem.2017.12.017.

• Protocol for M(3)P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma.

  Barrio S, DáVia M, Bruins L, Stühmer T, Steinbrunn T, Bittrich M, Einsele H, Stewart AK, Braggio E, Kortüm KM.
  Methods Mol Biol. 2018;1792:117-128. doi: 10.1007/978-1-4939-7865-6_8.